Compare SNGX & BQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNGX | BQ |
|---|---|---|
| Founded | 1987 | 2008 |
| Country | United States | China |
| Employees | N/A | 96 |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 6.1M |
| IPO Year | 2006 | 2020 |
| Metric | SNGX | BQ |
|---|---|---|
| Price | $0.39 | $0.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 245.5K | 120.2K |
| Earning Date | 05-08-2026 | 01-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $119,371.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.65 |
| 52 Week High | $6.23 | $72.74 |
| Indicator | SNGX | BQ |
|---|---|---|
| Relative Strength Index (RSI) | 46.90 | 47.34 |
| Support Level | $0.37 | $0.70 |
| Resistance Level | $0.38 | $0.89 |
| Average True Range (ATR) | 0.02 | 0.05 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 56.05 | 45.54 |
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Boqii Holding Ltd is a pet-focused platform in China. It offer a truly one-stop destination that pet parents in China may go to get everything it need for their pets and share their passion for pet parenting. It operate a pet-focused online retail business in China's pet market in terms of GMV. The company operates in single segment. This segment is engaged in pet products sales and online marketing and information services and other. All the company's revenues is derived from The PRC.